三个皮匠报告—— 严选型全行业研究报告分享下载平台,您的专属行业智库!
欢迎来到三个皮匠报告!
登录
帮助中心
首页
最新
研搜
BETA
合集
英文
会议
数据
财报库
政策库
自研报告
入驻
您的当前位置:
首页
>
行业数据
>
IGF-1R靶点药物国内竞争格局(I期及以上)
IGF-1R靶点药物国内竞争格局(I期及以上)
竞争格局
下载Excel
下载图片
原图定位
图片属性
图片格式:PNG
图片大小:222KB
图片尺寸:2314*935
同报告图片
/
4
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
所属报告:
信达生物-港股公司研究报告:肿瘤与综合线双驱动造就创新旗舰Biopharma-241020(44页).pdf
打包全文图表
相关数据
IGF-1R靶点药物国内竞争格局(仅统计临床进展达到I期及以上)
fCDoja/lk4HlkI3np7AgfCDkvZznlKjmnLrliLYgfCDnoJTlj5HmnLrmnoQgfCDnlr7nl4UgfCDkuK3lm73pmLbmrrUgfAp8LS0tLS0tLS0tLXwtLS0tLS0tLS0tLS0tLS0tfC0tLS0tLS0tLS0tLS0tLS18LS0tLS0tLS0tLS0tLS18LS0tLS0tLS0tLXwKfCDmm7/lpqXlsKTljZXmipcgfCBhbnRpLUlHRi0xUuWNleaKlyB8IOS/oei+vueUn+eJqSB8IOeUsueKtuiFuuebuOWFs+aAp+ecvOeXhSB8IOiOt+aJueS4iuW4giB8Cnwg55uW5bC85aGU5Y2V5oqXIHwgYW50aS1JR0YtMVLljZXmipcgfCBBbWdlbjsgSW1tdW5pdHlCaW87IFRha2VkYSBQaGFybWFjZXV0aWNhbHMgfCDog7DohbrnmYznrYkgfCBJSUnmnJ/kuLTluoogfAp8IGNvbnRlbHRpbmliIHwgQUxLOyBJR0YtMVLmipHliLbliYIgfCDotZvmnpfms7DljLvoja8gfCDpnZ7lsI/nu4bog57ogrrnmYznrYkgfCBJSUnmnJ/kuLTluoogfAp8IOael+ilv+abv+WwvCB8IElHRi0xUuaKkeWItuWJgjsgSW5zUuaKkeWItuWJgiB8IFNsaW5nIFRoZXJhcGV1dGljczsgQXN0ZWxsYXMgUGhhcm1hIHwg6IK+5LiK6IW655qu6LSo55mM562JIHwgSUnmnJ/kuLTluoogfAp8IENUMTAyIHwg5Y+N5LmJ55aX5rOVIHwg5Yab56eR6Zmi5pS+5bCE5LiO6L6Q5bCE5Yy75a2m56CU56m25omAO+aCpuW6t+iNr+S4miB8IOiCneeZjDvogp3nu4bog57nmYwgfCBJSeacn+S4tOW6iiB8CnwgTUhCMDE4QSB8IElHRi0xUi1GY+iejeWQiOibi+eZvSB8IOaYjuaFp+WMu+iNryB8IOeUsueKtuiFuuebuOWFs+aAp+ecvOeXhSB8IEkvSUnmnJ/kuLTluoogfAp8IFRTSFIvSUdGLTFS5Y+M5oqXIHwgYW50aS1UU0hSL0lHRi0xUuWPjOeJueW8guaAp+aKl+S9kyB8IOS4iua1t+W4guesrOS5neS6uuawkeWMu+mZoiB8IOeUsueKtuiFuuebuOWFs+aAp+ecvOeXhSB8IEnmnJ/kuLTluoogfAp8IFBIUDEwMDMgfCBhbnRpLUlHRi0xUuWNleaKlyB8IOaZruS5kOW6t+WMu+iNryB8IOeUsueKtuiFuuebuOWFs+aAp+ecvOeXhSB8IEnmnJ/kuLTluoogfAp8IDY4R2EtTk9EQUdBLVpJR0YtMVI6NC40MCB8IGFudGktSUdGLTFS5oqX5L2T5YG26IGU5qC457SgIHwg5ZOI5bCU5ruo5Yy756eR5aSn5a2mIHwg6Z2e5bCP57uG6IOe6IK655mM562JIHwgSeacn+S4tOW6iiB8CnwgdmVsaWdyb3R1ZyB8IGFudGktSUdGLTFS5Y2V5oqXIHwgQWJiVmllOyBaZW5hcyBhOyBWaXJpZGlhbjsgU2Fub2ZpIHwg55Sy54q26IW655u45YWz5oCn55y855eF562JIHwgSeacn+S4tOW6iiB8Cnwg5pu/5aal5pyo5Y2V5oqXIHwgYW50aS1JR0YtMVLljZXmipcgfCDljZrnnrvnlJ/niakgfCDlj4LogIPljp/noJQgfCBJ5pyf5Li05bqKIHwKCui1hOaWmeadpea6kO+8mkluc2lnaHTmlbDmja7lupPvvIjmiKroh7MyMDI15bm0M+aciDI45pel77yJ77yM5rWZ5ZWG6K+B5Yi456CU56m25omA
收藏
竞争格局
2025-04-29
原图定位
查看详情
国内在研的IGF-1R靶点药物临床进度总结
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
收藏
行业数据
2025-03-14
原图定位
查看详情
IBI311(替妥尤单抗,IGF-1R)RESTORE-1三期研究结果
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
收藏
行业数据
2025-03-14
原图定位
查看详情
IBI311(替妥尤单抗,IGF-1R)作用机理
fCDpobnnm64gICAgICAgICAgICAgICAgICAgICB8IOaPj+i/sCAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwKfC0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS18CnwgVFNI5Y+X5L2T5oqX5L2TICAgICAgICAgICAgICAgICAgIHwgVFNIIHJlY2VwdG9yIGFudGlib2RpZXMgICAgICAgICAgICAgICAgIHwKfCBUU0jlj5fkvZMgICAgICAgICAgICAgICAgICAgICB8IFRTSCByZWNlcHRvciAgICAgICAgICAgICAgICAgICAgICAgICAgICB8Cnwg552R5p2/6IW657uG6IOeICAgICAgICAgICAgICAgICAgIHwgT3JiaXRhbCBmaWJyb2JsYXN0ICAgICAgICAgICAgICAgICAgICAgIHwKfCBJR0YtMeWPl+S9kyAgICAgICAgICAgICAgICAgICB8IElHRi0xIHJlY2VwdG9yICAgICAgICAgICAgICAgICAgICAgICAgICB8CnwgY0FNUCAgICAgICAgICAgICAgICAgICAgIHwgY0FNUCAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwKfCBQSTNLICAgICAgICAgICAgICAgICAgICAgfCBQSTNLICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgfAp8IG1UT1IgICAgICAgICAgICAgICAgICAgICB8IG1UT1IgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICB8CnwgQWt0ICAgICAgICAgICAgICAgICAgICAgIHwgQWt0ICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwKfCDohILogqrnlJ/miJAgICAgICAgICAgICAgICAgICAgICB8IEFkaXBvZ2VuZXNpcyAgICAgICAgICAgICAgICAgICAgICAgICAgICB8Cnwg6YCP5piO6LSo6YW477yISEHvvInlkIjmiJAgICAgICAgICAgICAgfCBIeWFsdXJvbmljIGFjaWQgKEhBKSBzeW50aGVzaXMgICAgICAgICAgfAp8IOedkeadv+iEguiCque7huiDniAgICAgICAgICAgICAgICAgfCBPcmJpdGFsIGFkaXBvY3l0ZXMgICAgICAgICAgICAgICAgICAgICAgfAp8IOecvOectuiCjOiCieWSjOiEguiCque7hOe7h+aJqeWxlSAgICAgICAgIHwgRXhwYW5kZWQgb3JiaXRhbCBtdXNjbGVzIGFuZCBhZGlwb3NlIHRpc3N1ZSB8CgrotYTmlpnmnaXmupDvvJrkv6Hovr7nlJ/niakyMDI05bm0M+aciOaKlei1hOiAhea8lOekuu+8jOeUs+S4h+Wuj+a6kOeglOeptg==
收藏
行业数据
2025-03-14
原图定位
查看详情
SY707除ALK外针对靶点IGF1R、PTK2B、FAK更差异化
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
收藏
行业数据
2023-05-19
原图定位
查看详情
最新数据
全球全年龄段奶粉市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球酸奶及发酵乳制品市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球药用级益生菌市场规模(百万美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球益生菌膳食补充剂市场规模及增速
收藏
行业数据
2026-07-30
原图定位
查看详情
全球拥有AKK专利菌株的核心企业
收藏
行业数据
2026-07-30
原图定位
查看详情
基于此研究,2024 年 5 月 21 日,IBI-311 的上市申请获得药监局受理,而后 5 月 22日,CDE 网站显示,将公司的替妥尤单抗注射液(IBI311)拟纳入优先审评,用于甲状腺眼病。
竞争格局
原图定位
当前图表所属:
信达生物-港股公司研究报告:肿瘤与综合线双驱动造就创新旗舰Biopharma-241020(44页).pdf
RET靶点药物的国内竞争格局(NDA及以上)
VEGF/VEGFR靶点单抗药物的国内竞争格局(III期及以上)
Bcr-Abl靶点药物的国内竞争格局(III期及以上)
利妥昔单抗国内竞争格局(NDA及以上)
下载图片或Excel,需升级至尊VIP会员或「预见者」VIP
立即去升级
客服
商务合作
小程序
服务号
回到顶部
折叠
微信扫码登录
微信扫码登录
双重福利,扫码领取!
关注公众号『三个皮匠报告』,免费领取报告
1.100+最新优质行业报告
2.每周免费精选报告分享
手机快捷登录
账号登录
记住密码
忘记密码?
验证即登录,未注册将自动创建账号
获取验证码
收不到验证码注意事项
登录代表您已阅读并同意
《三个皮匠服务条款》